Pharmaceutical Statistics

Table of Contents

Pharmaceutical Statistics - Early View Articles



Nonlinear mixed‐effects models with misspecified random‐effects distribution

  • Author: Reza Drikvandi
  • Pub Online: Oct 29, 2019
  • DOI: 10.1002/pst.1981 (p )

Estimation of group means when adjusting for covariates in generalized linear models

  • Author: Yongming Qu, Junxiang Luo
  • Pub Online: Nov 18, 2014
  • DOI: 10.1002/pst.1658 (p )

Implementation of maximin efficient designs in dose‐finding studies

  • Author: Ellinor Fackle‐Fornius, Frank Miller, Hans Nyquist
  • Pub Online: Nov 18, 2014
  • DOI: 10.1002/pst.1660 (p )

Impact of selection bias on the evaluation of clusters of chemical compounds in the drug discovery process

  • Author: Ariel Alonso, Elasma Milanzi, Geert Molenberghs, Christophe Buyck, Luc Bijnens
  • Pub Online: Nov 25, 2014
  • DOI: 10.1002/pst.1665 (p )

Likelihood approach for evaluating bioequivalence of highly variable drugs

  • Author: Liping Du, Leena Choi
  • Pub Online: Nov 19, 2014
  • DOI: 10.1002/pst.1661 (p )

Dose finding with continuous outcome in phase I oncology trials

  • Author: Yunfei Wang, Anastasia Ivanova
  • Pub Online: Nov 19, 2014
  • DOI: 10.1002/pst.1662 (p )

Validation of qualitative microbiological test methods

  • Author: Pieta C. IJzerman‐Boon, Edwin R. Heuvel
  • Pub Online: Nov 21, 2014
  • DOI: 10.1002/pst.1663 (p )

Teacher's Corner

The disagreeable behaviour of the kappa statistic

  • Author: Laura Flight, Steven A. Julious
  • Pub Online: Dec 03, 2014
  • DOI: 10.1002/pst.1659 (p )


Adaptive and repeated cumulative meta‐analyses of safety data during a new drug development process

  • Author: Hui Quan, Yingqiu Ma, Yan Zheng, Meehyung Cho, Christelle Lorenzato, Carole Hecquet
  • Pub Online: Jan 21, 2015
  • DOI: 10.1002/pst.1669 (p )

Main Paper

Evaluation of program success for programs with multiple trials in binary outcomes

  • Author: Meihua Wang, G. Frank Liu, Jerald Schindler
  • Pub Online: Feb 02, 2015
  • DOI: 10.1002/pst.1670 (p )


Design considerations in clinical trials with cure rate survival data: A case study in oncology

  • Author: Steven Sun, Grace Liu, Tianmeng Lyu, Fubo Xue, Tzu‐Min Yeh, Sudhakar Rao
  • Pub Online: Nov 20, 2017
  • DOI: 10.1002/pst.1840 (p )

Equivalence testing for similarity in bioassays using bioequivalence criteria on the relative bioactivity

  • Author: Corine Baljé‐Volkers, Thembile Mzolo, Erik Talens, Pieta IJzerman‐Boon, Edwin Van den Heuvel
  • Pub Online: Nov 06, 2017
  • DOI: 10.1002/pst.1832 (p )

A case study in identifying targeted patients population in major depressive disorder by enhanced enrichment design

  • Author: Peter Zhang, Kevin Carroll, Mary Hobart, Carole Augustine, Gary Koch
  • Pub Online: Nov 19, 2017
  • DOI: 10.1002/pst.1839 (p )

Estimation of discrete survival function for error‐prone diagnostic tests

  • Author: Abidemi K. Adeniji, Jesse Y. Hsu, Abdus S. Wahed
  • Pub Online: Nov 26, 2017
  • DOI: 10.1002/pst.1838 (p )

Some statistical considerations in the clinical development of cancer immunotherapies

  • Author: Bo Huang
  • Pub Online: Nov 02, 2017
  • DOI: 10.1002/pst.1835 (p )
Page:   Prev 1 2 3 Next

Related Topics

Related Publications

Related Content

Site Footer


This website is provided by John Wiley & Sons Limited, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ (Company No: 00641132, VAT No: 376766987)

Published features on are checked for statistical accuracy by a panel from the European Network for Business and Industrial Statistics (ENBIS)   to whom Wiley and express their gratitude. This panel are: Ron Kenett, David Steinberg, Shirley Coleman, Irena Ograjenšek, Fabrizio Ruggeri, Rainer Göb, Philippe Castagliola, Xavier Tort-Martorell, Bart De Ketelaere, Antonio Pievatolo, Martina Vandebroek, Lance Mitchell, Gilbert Saporta, Helmut Waldl and Stelios Psarakis.